Search

everythinglearnresearchcommunity

for

Search:↓

Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Estrogens significantly influence hair growth by interacting with receptors in hair follicles and may help regulate the hair growth cycle.

Stress can cause hair loss by negatively affecting hair follicles and this effect might be reversed with specific treatments.

Different scaffold patterns improve wound healing and immune response in mouse skin, with aligned patterns being particularly effective.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

Some drugs can cause hair loss, excessive growth, or color changes, often reversible but sometimes permanent.

Behçet's Disease may be caused by genetic and environmental factors leading to abnormal immune responses, and stress management and new treatments could improve patient outcomes.

Hepatitis C virus can cause skin diseases and dermatologists play a crucial role in identifying these conditions.

Most skin changes during pregnancy are harmless and temporary, but some can risk the fetus and need careful treatment.

Calcipotriol plus betamethasone with microneedling works better than tacrolimus for treating vitiligo.

ADM scaffolds help skin heal by promoting a healing-type immune response.

COVID-19 and hypopituitarism (reduced pituitary gland function) are linked, with the latter's related health issues potentially worsening COVID-19 outcomes, and COVID-19 possibly increasing risk for pituitary complications.

New JAK inhibitor drugs show promise for treating skin diseases but need more research on safety and effectiveness.

High levels of the protein Flightless I worsen ulcerative colitis symptoms in mice.

Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.

Leflunomide and anthralin may effectively treat severe alopecia areata.

Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.

A man lost all his hair permanently after hepatitis C treatment, a side effect not seen before.

Hepatitis C treatment may trigger complete hair loss, especially in those with a history of patchy hair loss, but hair usually grows back within a year.

Wnt5a may contribute to psoriasis by reducing skin cell growth, blocking skin cell maturation, and increasing inflammation.

Three characteristics of plasmacytoid dendritic cells help tell apart lupus-related hair loss from LPP.

Autoimmune hair loss may be linked to increased Th1 and Th17 cells and decreased Th2 cells.

The combination therapy was effective and well-tolerated, especially in young patients.

Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.

A patient with a severe type of hair loss experienced partial hair regrowth after treatment with a specific light therapy and a medication called interferon α2a.

Certain gene variations may increase the risk and severity of alopecia areata.

Leflunomide is more likely to help treat alopecia areata than cause it.

Imiquimod improved skin pigmentation in most patients with xeroderma pigmentosum and may prevent further skin cancer, but some treatments can have side effects.